Qu Biologics is a clinical-stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel class of immunotherapies designed to restore innate immune function in targeted organs. Its lead product, QBKPN SSI, is a first-in-class immune modulator intended to optimize immunity and barrier function in the lungs and to reprogram immune cells to correct age-related immune dysregulation. Qu Biologics has completed four Phase 2 studies in lung cancer, Crohn’s disease, and ulcerative colitis, and plans two additional Phase 2 randomized placebo-controlled studies in late-stage colon cancer and immunosenescence beginning in Q4 2022. The company is receiving advisory services and research and development funding of up to $6,659,050 from the National Research Council of Canada’s Industrial Research Assistance Program (NRC IRAP) to support a Phase II randomized, placebo-controlled trial (IS-01) of QBKPN. This follows prior NRC IRAP support of up to $2,780,109 for preclinical studies and manufacturing of the QBKPN drug product. Qu states the funding will enable it to double the size of its team and accelerate clinical development aimed at improving health outcomes in the elderly. Qu Biologics is a private clinical-stage biotech developing Site Specific Immunomodulators (SSIs), a novel class of immunotherapies designed to restore and mobilize innate immune function in targeted organs. The company has completed four Phase 2 studies in lung cancer, Crohn’s disease, and ulcerative colitis, with a fifth Phase 2 underway in colon cancer. Qu plans multiple additional randomized placebo-controlled Phase 2 studies, including trials targeting innate immune decline in the elderly and post-operative innate immune suppression, plus studies in colon, pancreatic, and lung cancers. The SSI platform is intended to direct multiple components of innate immunity rather than single receptors or cells. Recent financing will support expansion of science, manufacturing, and clinical teams to accelerate development and initiation of further trials. Leadership includes co-founder and CEO Dr. Hal Gunn and CMO Dr. Simon Sutcliffe, with Dr. Shirin Kalyan leading scientific innovation. Qu Biologics develops Site Specific Immunomodulators (SSIs), a platform of immunotherapies intended to stimulate innate immune responses in targeted organs and reverse immune dysregulation. Its lead lung-directed SSI, QBKPN, is being advanced for prevention and treatment of COVID-19 and has shown promising animal data reducing SARS-CoV-2 infection. The company says QBKPN restores innate immune function and may retain effectiveness against new viral variants and other respiratory or systemic infections. Qu received advisory services and up to $1,971,195 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), bringing the total NRC IRAP project amount to $2,200,959. The funding will support research and manufacturing, confirmation of protection against new COVID-19 variants, domestic production of QBKPN in Canada, expansion of R&D teams, and preparation of a COVID-19 clinical trial application. Qu is a clinical-stage company that has completed four Phase 2 studies and has a fifth Phase 2 underway, with additional Phase 2 oncology studies planned. Qu Biologics is a clinical-stage biotechnology company developing Site Specific Immunomodulators (SSIs), a novel class of immunotherapies designed to stimulate innate immune responses in targeted organs. The platform aims to restore immune balance and reverse chronic inflammation underlying diseases including inflammatory bowel disease, cancer, inflammatory lung disease, and arthritis. Qu has completed three Phase 2 studies in Crohn’s disease, ulcerative colitis, and lung cancer and has two Phase 2 studies underway in Crohn’s disease and colon cancer. The company announced an oversubscribed $8M financing to complete stage 1 of the RESTORE Phase 2 trial for moderate to severe Crohn’s disease and to advance its Phase 2 colon cancer study assessing activation of anti-cancer immune responses. Proceeds will also be used to expand the team and capacity and to progress the proprietary immunotherapy platform. Management includes co-founder and CEO Dr. Hal Gunn and CMO Dr. Simon Sutcliffe; the company cautioned that forward-looking statements are subject to risks and uncertainties. Qu Biologics develops Site Specific Immunomodulators (SSIs), a class of immunotherapies designed to stimulate an innate immune response in targeted organs or tissues to potentially reverse chronic inflammation. The company is developing QBECO SSI and has initiated clinical trials in Crohn's disease, ulcerative colitis and recurrent lung cancer. Qu Biologics was awarded $240,000 from Genome British Columbia to support a Phase 2a clinical trial of QBECO for moderate-to-severe ulcerative colitis. The Phase 2a study is investigating safety, tolerability, clinical response and remission, plus the immunologic mechanism of action of QBECO SSI. The trial will assess correlations between genetic polymorphisms associated with ulcerative colitis, the fecal microbiome, and QBECO SSI efficacy. The study has completed enrollment of the first group of participants and expects to begin enrollment of a second group in late 2016.

Total raised

$36M

Funding rounds

7

Latest round

Equity

Latest activity

Oct 2022